University of Queen
Mary London
Vitamin D supplements
protect against acute respiratory infections including colds and flu, according
to a study led by Queen Mary University of London (QMUL).
The study provides the
most robust evidence yet that vitamin D has benefits beyond bone and muscle
health, and could have major implications for public health policy, including
the fortification of foods with vitamin D to tackle high levels of deficiency
in the UK.
The results, published
in The BMJ, are based on a new analysis of raw data
from around 11,000 participants in 25 clinical trials conducted in 14 countries
including the UK, USA, Japan, India, Afghanistan, Belgium, Italy, Australia and
Canada.
Individually, these trials yielded conflicting results, with some reporting that vitamin D protected against respiratory infections, and others showing no effect.
Individually, these trials yielded conflicting results, with some reporting that vitamin D protected against respiratory infections, and others showing no effect.
Lead researcher Professor Adrian Martineau from QMUL said: "This major collaborative research effort has yielded the first definitive evidence that vitamin D really does protect against respiratory infections. Our analysis of pooled raw data from each of the 10,933 trial participants allowed us to address the thorny question of why vitamin D 'worked' in some trials, but not in others.
"The bottom line
is that the protective effects of vitamin D supplementation are strongest in
those who have the lowest vitamin D levels, and when supplementation is given
daily or weekly rather than in more widely spaced doses.
"Vitamin D
fortification of foods provides a steady, low-level intake of vitamin D that
has virtually eliminated profound vitamin D deficiency in several countries. By
demonstrating this new benefit of vitamin D, our study strengthens the case for
introducing food fortification to improve vitamin D levels in countries such as
the UK where profound vitamin D deficiency is common."
Vitamin D -- the
'sunshine vitamin' -- is thought to protect against respiratory infections by
boosting levels of antimicrobial peptides -- natural antibiotic-like substances
-- in the lungs.
Results of the study fit with the observation that colds and 'flu are commonest in winter and spring, when levels of vitamin D are at their lowest. They may also explain why vitamin D protects against asthma attacks, which are commonly triggered by respiratory viruses.
Results of the study fit with the observation that colds and 'flu are commonest in winter and spring, when levels of vitamin D are at their lowest. They may also explain why vitamin D protects against asthma attacks, which are commonly triggered by respiratory viruses.
Daily or weekly
supplementation halved the risk of acute respiratory infection in people with
the lowest baseline vitamin D levels, below 25 nanomoles per litre (nmol/L).
However, people with higher baseline vitamin D levels also benefited, although
the effect was more modest (10 per cent risk reduction). Overall, the reduction
in risk of acute respiratory infection induced by vitamin D was on a par with
the protective effect of injectable 'flu vaccine against 'flu-like illnesses.
Acute respiratory
infections are a major cause of global morbidity and mortality. Upper
respiratory infections such as colds and 'flu are the commonest reason for GP
consultations and days off work.
Acute lower respiratory infections such as pneumonia are less common, but caused an estimated 2.65 million deaths worldwide in 2013. Vitamin D supplementation is safe and inexpensive, so reductions in acute respiratory infections brought about by vitamin D supplementation could be highly cost-effective.
Acute lower respiratory infections such as pneumonia are less common, but caused an estimated 2.65 million deaths worldwide in 2013. Vitamin D supplementation is safe and inexpensive, so reductions in acute respiratory infections brought about by vitamin D supplementation could be highly cost-effective.
The study was
conducted by a consortium of 25 investigators from 21 institutions worldwide
and funded by the National Institute for Health Research.
Professor Hywel
Williams, director of the NIHR Health Technology Assessment (HTA) Programme
said: "The interesting findings of this large study are worthy of serious
further debate. This study is yet another example of how the NIHR HTA Programme
reaches the parts that other research funders may not tackle."